BioVie Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BioVie Inc. (BIVI) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $7.40 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-08-13
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2017-09-30 was $79.34K, a 52.93% decline year-over-year.
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2017-06-30 was $224.12K, a 106.47% increase year-over-year.
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2017-03-31 was $69.61K, a 225.26% increase year-over-year.
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2016-12-31 was $108.03K.
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2026 was $7.40M.
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $9.00M, a 60.71% increase from fiscal 2023.
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $5.60M, a 6.67% decline from fiscal 2022.
- BioVie Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $6.00M, a 1956.62% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month as first filed | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.40M 10-K · filed 2026-08-13 | |||||
| 2025-06-30 | $5.30M S-1/A · filed 2026-08-06 | |||||
| 2024-06-30 | $9.00M 10-K · filed 2024-09-30 | |||||
| 2023-06-30 | $5.60M 10-K · filed 2023-08-16 | |||||
| 2022-06-30 | $6.00M 10-K · filed 2023-08-16 | $5.97M 10-K · filed 2022-09-27 | ||||
| 2021-06-30 | $291.74K 10-K · filed 2022-09-27 | |||||
| 2017-09-30 | $79.34K 10-Q · filed 2017-11-08 | $303.46K derived: sum of 2 quarters · filed 2017-11-08 | $373.07K derived: sum of 3 quarters · filed 2017-11-08 | $481.10K derived: sum of 4 quarters · filed 2017-11-08 | ||
| 2017-06-30 | $224.12K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-24 | $293.73K derived: sum of 2 quarters · filed 2017-08-24 | $401.75K derived: sum of 3 quarters · filed 2017-08-24 | $570.30K 10-K · filed 2017-08-24 | ||
| 2017-03-31 | $69.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-09 | $177.63K derived: sum of 2 quarters · filed 2017-05-09 | $346.18K 10-Q · filed 2017-05-09 | $454.73K derived: sum of 4 quarters · filed 2017-11-08 | ||
| 2016-12-31 | $108.03K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-02-07 | $276.57K 10-Q · filed 2017-02-07 | $385.12K derived: sum of 3 quarters · filed 2017-11-08 | $406.52K derived: sum of 4 quarters · filed 2017-11-08 | ||
| 2016-09-30 | $168.55K 10-Q/A · filed 2017-01-19 | $277.10K derived: sum of 2 quarters · filed 2017-11-08 | $298.50K derived: sum of 3 quarters · filed 2017-11-08 | $200.07K derived: sum of 4 quarters · filed 2017-11-08 | ||
| 2016-06-30 | $108.55K derived: 10-Q 12 month − 10-Q 9 month · filed 2017-11-08 | $129.95K derived: sum of 2 quarters · filed 2017-11-08 | $31.52K derived: sum of 3 quarters · filed 2017-11-08 | $168.55K 10-Q · filed 2017-11-08 | ||
| 2016-03-31 | $21.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-23 | -$77.03K derived: sum of 2 quarters · filed 2016-05-23 | $60.00K 10-Q · filed 2016-05-23 | $81.40K derived: sum of 4 quarters · filed 2017-01-19 | ||
| 2015-12-31 | -$98.43K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2016-02-16 | $38.60K 10-Q · filed 2016-02-16 | $60.00K derived: sum of 3 quarters · filed 2017-01-19 | $79.00K derived: sum of 4 quarters · filed 2017-01-19 | ||
| 2015-09-30 | $137.03K 10-Q/A · filed 2017-01-19 | $17.80K 10-Q · filed 2015-11-13 | $158.43K derived: sum of 2 quarters · filed 2017-01-19 | $177.43K derived: sum of 3 quarters · filed 2017-01-19 | $205.03K derived: sum of 4 quarters · filed 2017-01-19 | |
| 2015-06-30 | $21.40K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | $40.40K derived: sum of 2 quarters · filed 2016-09-28 | $68.00K derived: sum of 3 quarters · filed 2016-09-28 | $90.90K 10-K · filed 2016-09-28 | ||
| 2015-03-31 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $46.60K derived: sum of 2 quarters · filed 2015-05-11 | $69.50K 10-Q · filed 2015-05-11 | $120.00K derived: sum of 4 quarters · filed 2015-05-11 | ||
| 2014-12-31 | $27.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-05 | $50.50K 10-Q · filed 2015-02-05 | $101.00K derived: sum of 3 quarters · filed 2015-05-11 | $49.80K derived: sum of 4 quarters · filed 2015-05-11 | ||
| 2014-09-30 | $22.90K 10-Q · filed 2014-11-13 | $73.40K derived: sum of 2 quarters · filed 2015-05-11 | $22.20K derived: sum of 3 quarters · filed 2015-05-11 | |||
| 2014-06-30 | $50.50K 10-Q · filed 2015-05-11 | $125.50K 10-Q · filed 2014-11-13 | -$700.00 derived: sum of 2 quarters · filed 2015-05-11 | $125.50K 10-K · filed 2015-10-01 | ||
| 2014-03-31 | -$51.20K 10-Q · filed 2014-05-09 | |||||
| 2013-12-31 | -$44.30K 10-Q · filed 2014-05-09 | |||||
| 2013-06-30 | -$6.90K 10-Q · filed 2014-05-09 | $6.90K 10-K · filed 2014-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |